Nexus Pharmaceuticals received U.S. Food and Drug Administration approval for the company’s New Drug Application for Emerphed, the first premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
The U.S. Food and Drug Administration approved an expanded indication for Sanofi’s Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages 6 years and older. The expanded indication approved by the FDA applies to both type 1 and 2 diabetes. Previously, Toujeo was U.S.-approved only for adults aged 18 years and older.
Johnson & Johnson filed for an approval from European regulators for the company’s two-dose experimental vaccine to protect against Ebola.
The U.S. Food and Drug Administration approved Janssen’s Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.
Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.
Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.
Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.
Almost three in four U.S. allergy specialists are prescribing tablets to ease symptoms caused by pollen, ragweed and dust at least some of the time, though they have not completely shifted away from allergy shots, a survey suggests.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
